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Abstract 
The aim of this study was to assess participants perceptions and 
preferences for inhaler devices; and the relationship of  inhaler technique  
to the decision making process . A mixed-methods approach including a 
semi-structured interview, Patient Satisfaction and Preference 
Questionnaire (PASAPQ) and inhalation technique assessment were 
employed. A total of 25 participants with at least one inhaler were 
recruited. The interviews analyzed qualitatively. In addition, each 
participant received a score for PASAPQ in regards to satisfaction with 
performance, satisfaction with convenience and overall satisfaction. 
Participants’ inhalation technique was assessed.  Two matrices were 
generated to identify any patterns of association between participants 
perception from qualitative interviews, with participants satisfaction and 
preference (PASAPQ) with regards to correct and incorrect use of inhalers. 
Triangulation of data revealed that there did not appear to be a relationship 
between patient satisfaction with inhaler device, preference, inhalation technique 
and level of choice in decision-making. There are other factors influencing patient 
opinions of inhaler devices rather than physical features of inhalers including the 
level of asthma control, effectiveness of medication in relieving asthma symptoms 
and length of time of use of inhalers. Participants did not differentiate the device 
from medication and this affected not only their perception about inhaler devices 
but also their perception about inhalation technique. This research further 
highlights the lack of understanding of the relevant role of inhaler devices in 
asthma management. 
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Introduction 
 
1.1. Prevalence of Asthma 
Asthma as a chronic inflammatory disease has a major impact on the lives of 
people with the condition. It affects different age groups and associates with poor 
quality of life (1) and life expectancy. Three hundred million people worldwide 
have been affected by asthma with the average range of 1-18% in different 
countries. It has been accounted for 250000 annual deaths in all over the world 
(2). The number of people affected by asthma has increased in recent decades due 
to the impact of western lifestyle, industrialization and urbanization (3), air 
pollution and higher usage of antibiotics (4).  
 
In Australia with one of the highest prevalence of asthma, 2.2 million people (14-
16% of children and 10-12% of adults) have been affected. In 2004-2005, $606 
million of the Federal budget was spent on asthma; with the higher asthma-
related costs being associated with the expenditure on prescription 
pharmaceuticals (1). 
 
1.2. Asthma management  
When it comes to the management of asthma, although medicines are considered 
the cornerstone, effective asthma control often consists of a multifaceted 
approach (3). Asthma management consists of various strategies to achieve and 
maintain control of the disease (2). A number of management guidelines have 
been developed, which identify and describe the key elements to optimal asthma 
management (5). These include guidelines for the diagnosis of asthma, the 
development of asthma management plans, including the need to optimise lung 
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function, decrease symptoms, avoid exposure to trigger factors, appropriate 
medication, written self-management plans and regular asthma review (3). 
 
It is worth noting that Asthma Management Guidelines stress the importance of 
not only the appropriate and correct use of medicines but also the need for 
patients to be able to effectively self-manage their medication through the use of 
Asthma Action Plans. Asthma Action Plans are personalized written asthma self-
management plans, which are written by the medical practitioner, and outline the 
way in which patients should modify their medication regimen, based on their 
asthma symptoms (1). The importance in Asthma Action Plans lies in the 
contribution of patients in self management of asthma to increase the adherence 
and optimise treatment cost. This is associated with patient better understanding 
to deal with asthma exacerbation by adjusting doses of controller and reliever 
medications (6).  
 
One thing, however, that guidelines do not address are the hidden barriers to 
asthma control. In particular, those associated with the type of inhaler device 
used, this being shown to be a vital consideration in medication selection (6). 
Patients with various preferences and perceptions will master better inhalation 
techniques for a certain device rather than others (7). Regardless of the actual 
drug, a device plays a significant role in treatment result in long term. Selecting an 
inhaler for a patient should be tailored based on their needs of medication as well 
as their ability to use the device. 
 
Unfortunately, despite the availability of management guidelines, asthma still 
remains a poorly controlled condition. This has been attributed to sub-optimal 
management of asthma, including the difficulty of implementing guidelines into 
practice (5) the lack of time for health care professionals to employ them (8) as 
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well as patients’ attitude and medication use (adherence and  inhalation 
technique) (5).Patients negative attitude towards asthma medication may impact 
on patient willingness to use medication appropriately (7). 
 
1.3. Medications 
Medications play a fundamental role in asthma management. The overall aim of 
medication therapy in asthma is to optimise asthma control with the lowest 
effective doses of medication. While there is no cure for asthma, this is the 
ultimate aim of medication management. Although a variety of medications in a 
range of dosing devices are available to either relieve symptoms or control the 
disease; it remains that inhalation therapy is the preferred route of administration. 
For the optimal management of asthma, medication administration through 
inhalation is preferred due to it enabling greater effectiveness and fewer side 
effects than delivery of medication via oral and parental route (2, 9, 10).  
 
When it comes to the classification of asthma medications, they are categorized 
into three main categories of relievers, preventers and symptom controllers. 
Relievers, including short acting beta agonists and Ipratropium bromide are 
recommended on an as needed basis to relieve the symptoms. Preventers mainly 
contain inhaled corticosteroids and are recommended on a regular basis to 
prevent exacerbation and control the disease. Occasionally oral corticosteroids are 
recommended to treat severe asthma exacerbations. Symptom controllers are 
long acting beta agonists being recommended to use as an adjunct therapy with 
corticosteroids to control asthma symptoms (3, 4). A stepwise therapy is 
recommended for controlling asthma symptoms with dose adjustment of 
therapies based on asthma severity and exacerbation (4). 
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1.3.1. Reliever medication 
Fast acting beta-2 agonists are used to relieve acute asthma bronchospasm as 
their fast onset of action make them treatment of choice in acute exacerbation of 
asthma as well as in the prevention of exercise induced asthma . These agents 
cause relaxation of the bronchial smooth muscle (6). They are administered via 
inhalation, however can result in side effects consistent with beta-2 
adrenoreceptor stimulation such as restlessness and tremor, even in 
recommended doses (3, 6).  
Table 1 is the summary of different short acting beta-2 agonists available in the 
Australian market through various devices and recommended dosage for adult 
and children. 
 
Despite their significant role in therapy, over reliance on rapid acting beta agonists 
leads to ignorance of asthma exacerbation and necessity of preventive measures 
(11). As a result, recommended usage is as needed basis on the lowest possible 
dosage. Frequency of administration is an indicator of asthma exacerbation and 
necessitates preventive therapy initiation (3, 12). 
 
Table 1: Short acting beta-2 agonists (6) 
Medication Device Brand  
Adult  
and children dose 
 
Salbutamol 
 
pMDI 
 
Ventolin® 
100-200 mcg as required every 
3-6 hours  
Salbutamol Autohaler® Airomir® 
100-200 mcg as required every 
3-6 hours 
 
Terbutaline 
 
 
Turbuhaler® 
 
Bricanyl® 
500 mcg as required every 3-6 
hours 
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1.3.2. Preventer medications 
Of particular interest in the medication management of asthma, is the use of the 
preventer class of asthma medications. They are of particular importance in the 
management of asthma and successful asthma management is highly reliant on 
these medications. There are several drug classes within the preventer domain.  
 
1.3.2.1 Inhaled Glucocorticoids 
Glucocorticoids in general and inhaled glucocorticoids in particular, are the 
mainstay in achieving asthma control and preventing breakthrough exacerbations 
(13, 14). Inhaled glucocorticoids inhibit inflammation in the airways (4, 15) and 
with regular use have been shown to reduce asthma mortality by improving lung 
function (16), reducing the frequency and severity of asthma exacerbations (3, 17) 
and preventing irreversible airway limitation in susceptible patients (5). Variety of 
glucocorticoids are available through different delivery devices (3, 6, 15, 16). Table 
2 summarizes the range of inhaled glucocorticoids currently available on the 
Australian market, the devices in which they are available and recommended dose 
range for adults and children. 
 
The main side effects of inhaled glucocorticoids are local adverse effects, including 
oropharyngeal candidiasis and hoarse voice, which can be prevented through the 
correct use of the inhalers and by mouth rinsing after inhalation. At higher doses, 
(>500 mcg/day for Beclometasone dipripionate and > 800 mcg/day for 
Budesonide) long term treatment can result in systemic absorption (6) and an 
increased risk of osteoporosis, adrenal suppression, cataract, glaucoma and 
bruising highlighting the need for appropriate medication use. 
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Table 2: Recommended daily dosage of inhaled glucocorticoids (6) 
Medication Device Brand  Adult dose 
Children ≥ 5 
years old 
dose 
Beclomethasone 
dipropionate–HFA 
pMDI 
Autohaler® 
Qvar® 50-200 mcg 
BD 
50 mcg BD 
Budesonide Turbuhaler® Pulmicort® 
400-2400 
mcg/day 
200-800 
mcg/day 
Fluticasone 
propionate 
pMDI 
Accuhaler® 
Flixotide® 100-500  mcg 
BD 
50-250 mcg BD 
Ciclesonide pMDI Alvesco® 
80-320 
mcg/day 
N/A 
 
 
1.3.2.2. Leukotriene receptor antagonists 
Leukotriene antagonists are anti-inflammatory agents, available in oral form only. 
Currently, there is only one available on the Australian market (montelukast, 
Singulair®). Generally less effective than small doses of inhaled corticosteroids in 
reduction of bronchial inflammation and improvement of lung function, their role 
in treatment is limited to treatment of aspirin-sensitive asthma and prevention of 
exercise induced asthma. They are recommended as add on therapy to inhaled 
corticosteroids (ICS) when long acting beta-2 agonists (LABA) are not effective or 
tolerated (13, 16). 
 
1.3.2.3. Theophylline 
Theophylline, available in oral form only, is an anti-inflammatory agent and 
bronchial muscle relaxant is employed in controlling asthma symptoms. Due to a 
narrow therapeutic index and side effects, it is no longer recommended as a first 
line therapy in asthma patients (3, 5). It is recommended as add on therapy when 
ICS are not effective alone after treatment failure of LABA and leukotriene 
antagonists (3, 16). 
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1.3.3. Symptom relievers  
 
1.3.3.1 Long acting beta-2 agonists 
Due to the concerns associated with the use of high dose corticosteroids, inhaled 
long acting beta-2 agonists (LABA), used in combination with ICS have been shown 
to be effective when used with corticosteroids in reducing nocturnal symptoms, 
improving lung function and reduction of reliever measures thereby avoiding the 
need to increased ICS doses (12, 17). Table 3 summaries the range of ICS + LABA 
products currently available on the Australian market, the devices in which they 
are available and recommended dose range for adults and children. It should be 
noted that these products include both an ICS and a LABA, hence are known as 
combination products. The advantage of the combination products over drug 
administrator through one inhaler rather than two is increased adherence to 
treatment as Haughney et al, (2007) has shown that patients prefer to use fewer 
inhalers and lowest dose of inhaled corticosteroid (13). Therefore, combination 
inhalers can increase adherence to treatment while allowing for the lowest 
effective daily dosage of corticosteroids to be administered (12). 
Table 3: Recommended daily dosage of long acting beta-2 agonists (6) 
Medication Device Brand  Adult dose Children > 4 
years old 
Budesonide and 
Formoterol 
Turbuhaler® Symbicort® 
1-2 inhalation 
BD and prn as 
reliever  
N/A 
Fluticasone  
and Salmetrol 
pMDI Seretide® 
Two inhalation 
BD 
Two inhalation 
BD of 50 mcg 
Fluticasone  
and Salmetrol 
Accuhaler® Seretide® 
One inhalation 
BD 
One inhalation 
BD of 100 mcg 
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1.4. Medication delivery in asthma 
While several different types of medications are commonly used in the medication 
management of asthma, a vast majority of them are available through inhalation 
devices. The concept of direct medication delivery to the lungs allows rapid onset 
of action (18) and high local concentration (19) with smaller dose and better 
efficacy with relatively lower adverse effect, which maximises patient adherence 
to therapy (19, 20). The significant role of an efficient inhaler in treatment process 
(20) has led to introduction of several inhaler devices to the market with the most 
commonly used in the treatment of asthma are the pressurised metered dose 
inhalers (pMDIs) and the dry powder inhalers (DPIs) (21). This significantly changes 
the management of asthma as patients are required to engage with their 
medication in a different way. Knowledge and skills were required to not only 
know which medication to use, but also how to physically administer medication 
via an inhaler device. That is, several steps are required to be performed correctly 
to ensure of optimum drug delivery. Various operation of each inhaler 
necessitates different inhalation maneuver to maximise the lung deposition of 
medications (22). In general, preparation of the inhaler, exhalation and inhalation 
maneuver and actuation and post actuation steps are required for all inhalers (23). 
Table 4 summarises the inhalation technique steps for each device type.   
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Table 4: Inhalation technique steps  
Pressurised Metered Dose Inhaler 
 
1. Remove mouthpiece cover and shake well. 
2. Exhale all air out of lungs.  
3. Keep head upright, lift chin slightly. 
4. Mouthpiece between teeth and seal with lips. 
5. Inhale slowly and press canister early. 
6. Continue slow and deep inhalation. 
7. Hold breath for as long as is comfortable (aim for 10 seconds). 
8. Breathe out normally, away from the inhaler. 
9. Replace cap. 
 
Pressurised Metered Dose Inhaler+ Spacer 
         
  
Single Breath Technique Method 
 
1. Assemble the spacer. 
2. Remove mouthpiece cover of inhaler, shake and insert into spacer. 
3. Exhale all air out of lungs. 
4. Keep head upright, lift chin slightly. 
5. Spacer mouthpiece between teeth and seal with lips. 
6. Press canister and inhale slowly and deeply from spacer. 
7. Hold breath for as long as is comfortable (aim for 10 seconds). 
8. Breathe out normally. 
 
 
Pressurised Metered Dose Inhaler+ Spacer  
  
         
Multiple Breath Technique Method 
 
1. Assemble the spacer. 
2. Remove mouthpiece cover of inhaler, shake and insert into spacer. 
3. Exhale all air out of lungs. 
4. Keep head upright, lift chin slightly. 
5. Spacer mouthpiece between teeth and seal with lips. 
6. Breathe in and out of spacer, then press canister. 
7. Continue to breathe normally through spacer for a few breaths. 
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Autohaler® 
 
1.   Remove inhaler cap and shake well. 
2.   Raise lever up to prepare device.     
3.   Exhale all air out of lungs.    
4.   Keep head upright, lift chin slightly. 
5.   Place mouthpiece between teeth and seal with lips. 
6.   Inhale slowly and deeply. 
7.   Hold breath for as long as comfortable (aim for 10 seconds). 
8.   Breathe out normally away from inhaler. 
9.  Push lever down and replace cap. 
 
Turbuhaler® 
 
1.  Unscrew and remove the cap from the inhaler. 
2.   Keep inhaler upright. 
3.   Rotate grip one way, then back, to load dose. 
4.   Exhale all air out of lungs. 
5.   Exhale away from the mouthpiece. 
6.   Keep head upright, lift chin slightly. 
7.   Place mouthpiece between teeth and seal with lips. 
8.   Inhale forcefully and deeply.  
9.   Pause, then breathe out normally. 
10. Exhale away from the inhaler.   
11. Replace cap. 
 
Accuhaler® 
 
1.   Open Inhaler.  
2.   Push lever back completely to load dose. 
3.   Exhale all air out of lungs. 
4.   Exhale away from the mouthpiece. 
5.   Hold inhaler horizontally. 
6.   Place mouthpiece between teeth and seal with lips. 
7.   Inhale slowly and deeply. 
8.   Hold breath for as long as is comfortable (aim for 10 seconds). 
9.   Exhale away from the inhaler. 
10. Close Inhaler. 
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1.5. Poor inhalation technique  
These inhaler devices are used to deliver a range of medications in the treatment 
of asthma and in terms of their use, all have their advantages and disadvantages 
however, the one most common feature of inhaler device is the extent to which 
patients use them incorrectly. Up to 94% (24-28) of patients do not use their 
inhalers correctly and even after education, require further follow-up education to 
ensure that they maintain correct technique over time (29-31).  
 
Pressurised Metered Dose Inhalers are the most prescribed devices (32) used for 
the delivery of reliever medication and while they have the advantages of being 
cost-effective (33) and portable, their correct use require the co-ordination of a 
breathing maneuver and activation of the device, which is problematic for most 
patients (32, 34-36). UP to 96% (21, 33, 37) of patients do not use their pMDIs 
correctly where co-ordination of actuation and inhalation is the major error made 
by patients. They generally prime the device too early or too late which effects 
drug delivery to the lungs (38). In addition, despite the common belief about 
necessity of rapid and forceful inhalation with pMDIs, slow and deep inhalation is 
required to minimize the oropharyngeal delivery of medication (29) and increase 
the peripheral deposition (38). Moreover, the majority of patients fail to hold their 
breath after inhaling a dose which is necessary for best drug delivery (38). In 
summary, due to different natural breathing pattern of patients, pMDIs are 
recommended devices for patient with slower pattern of breathing(29). 
 
On the other hand, the main advantage of DPIs is that they are breath actuated, 
thereby do not require co-ordination and match the patients with fast inhalation, 
while still remaining highly portable (33). In Australia, the most commonly used 
DPIs in the management of asthma are the Turbuhaler® and Accuhaler® .However, 
once again, despite the fact that co-ordination is not required, DPIs inhaler 
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technique continues to be problematic (7, 39) with up to 94% of patients failing to 
demonstrate correct inhaler technique (26).Technique maintenance is once again 
a problem with DPI use (30, 31) . The concern is that major errors are made with 
handling a device and obviously with DPIs patients play a significant role in 
preparing a dose and making it ready for inhalation(38). In addition, fast and deep 
inhalation is required to deliver the dose to lungs which is problematic in patient 
with insufficient inspiratory flow, children and elderly (29, 32, 33).  
 
The implications of incorrect inhaler technique are significant with poorer asthma 
control, lung function, quality of life and perceived control of asthma being linked 
to poor inhaler technique (30). Therefore, the success of inhalation therapy is 
extremely dependent of correct use of inhalers for optimal drug delivery. Incorrect 
use of inhalers contributed to patients’ belief that the medication is not useful for 
their symptoms and lead to non adherence (7, 22). 
 
1.6. Possible reasons for poor technique 
Undoubtedly correct technique is an integral part of asthma control. Despite 
availability of various inhalers, if handled incorrectly, there is no difference 
amongst different inhalers in effectiveness of treatment (40). There has been 
much research attempting to understand the reasons for poor technique and the 
ways in which inhaler technique can be improved and maintained over time. 
Research shows that some of the potential reasons for poor inhaler technique are 
linked to the device, the patient and the health care professional (37). 
 
1.6.1. The role of the device 
There are different classifications for devices based on generation of aerosol, 
particle size, formulation, whether they are single dose or multi dose inhalers.  
Various inhalers require mastering different skills to achieve the optimal effect of 
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medication (34) which may be a limitation for younger patients and elderly. Some 
devices are easier to use than others for some patients due to various technique 
steps. Therefore, device selection is important and healthcare professionals need 
to be aware of this when prescribing inhalers.    
 
1.6.2. The role of health care professionals  
Health care professionals also play an important role in patient achievement of 
correct technique although they presented difficulties in mastering technique due 
to lots of different devices in the market (22, 33, 34, 41). It has been suggested 
most critical errors occurs when patients are not provided with optimal training 
(42) or they use more than one type of inhaler (18). Verbal instructions along with 
physical demonstration and written instruction (22, 39) is deemed to be the most 
effective way for patient training, that is step by step demonstration of correct 
technique from health care professionals alongside verbal instruction to achieve 
optimal technique (36, 39). By following this process of education, almost all 
patients are able to develop the appropriate skills. However, initial training is not 
enough as following training, 39% of patients do not maintain correct technique 
(43). Therefore, the initial training should be followed by regular reviewing and   
re-education to ensure that correct technique is maintained over time (33, 36). 
 
1.6.3. The role of the patient 
Patients as the actual inhaler users play a significant role in mastering correct 
technique. Patient related factors are categorized as person’s attitude and 
behaviour and physical features of inhalers. 
 
1.6.3.1. Physical feature of inhalers 
Physical features of inhalers have a major effect on achieved technique (26). There 
are several factors which may influence patient mastering correct technique such 
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as age (35), the natural pattern of breathing, incorrect handling of a device. For 
instance, insufficient inspiratory flow limited the administration of DPIs in elderly 
and children (29) or the patient’s natural pattern of breathing does not meet the 
criteria for specific inhaler to be employed. Some patients inhale too fast or too 
slow as a result unable to use pMDI and DPIs respectively (29). 
 
1.6.3.2. Patients’ attitude and behavior 
Patients’ attitude towards medication, adherence and preference for inhalers is 
another feature suggested playing a crucial role in correct inhalation technique 
achievement (44). Patients’ non adherence to treatment is highly influenced by 
their beliefs about medication. Although patient rarely differentiate between 
actual drug and inhaler device in terms of outcome, those with positive attitudes 
and preference toward their therapy show better adherence to treatment (45-47) 
and better technique (44, 45). To meet patient needs in achieving appropriate 
technique, physician’s choice should be tailored based on patient preference and 
needs.  In this way, shared treatment decision making is one of the recommended 
strategies.   
 
1.7. Patients and treatment decision making 
 Shared Treatment Decision Making (STDM) is the process of finalizing the 
treatment where patient preference recognized and took into account by 
physician and both patient and physician achieve agreement on the ultimate 
result (48, 49). It is well established in the literature that patients’ adherence to 
treatment regimen is highly influenced by their active participation in treatment 
decision-making (50-52). Taking into account patient’s opinion in choosing the 
medication may lead to not only satisfaction with treatment but also better 
adherence to therapy and successful therapeutic outcome (53). Physicians play a 
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fundamental role in addressing patient preference and perception to build up a 
good relationship and achieve treatment goals (54). 
 
Preference of involvement in the treatment decision making is influenced by age, 
level of education (55), severity of disease, characteristic of health professional 
(56), trust (57) and previous experience with disease where passive role is more 
preferred by older and less educated people (55, 56). Asthma as lifelong condition 
necessitates more involvement in decision-making to increase compliance with 
therapy. 
 
While patient active participation in decision-making has been shown to result in 
positive outcomes, still a number of patients prefer to rely on physician decision 
where 43.7% of asthma patient presented preference for the passive role in 
decision- making due to lack of consultation time, lack of knowledge, severity of 
disease and physician unwillingness to accept patient opinion (56). Several studies 
explored treatment decision-making in asthma management presented various 
results with regards to the extent and type of participation patient prefer. Small 
and colleagues, (2010) investigated the effect of patient- physician partnership on 
level of asthma control and quality of life. The results revealed a positive link 
between patient-physician participation and it’s effect on asthma management in 
long term, however emphasized the importance of patient education to be able to 
involve in decision-making (58). Adam et al, (2001) finding was inconsistent with 
the hypothesis of shared decision-making when patient preferred a passive role in 
the process, while retaining some degree of involvement (56). In addition, Gibson 
et al, (1995) found asthma patients would like to be informed about their 
condition, however prefer to rely on physician’s decision-making to manage 
asthma exacerbation (59).  
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1.8. Inhalers and patient satisfaction 
Patient satisfaction of their medications particularly in chronic diseases has been 
found to be very important in terms of the success of medication treatment. 
Increased patient satisfaction and positive perceptions of medication have been 
linked with increased adherence to medication and patient outcomes (60-63). 
That is, when patients are satisfied, they comply with treatment regimens which 
lead to optimal control of disease (53) and better clinical outcomes (64, 65).   
 
1.9. Inhaler devices selection 
Given the complexity associated with patient and the use of inhalers, the 
importance of marrying the right inhaler to the patient cannot be underestimated. 
Asthma guidelines have pinpointed variety of features to be taken into account 
when it comes to inhaler sections. First of all, the availability of therapeutics agent 
needs to be established. Then a series of additional physical and cognitive aspects 
need to be considered. Patient ability to use a device is one of the significant 
factors to be considered when choosing a device for a patient. Inhaler device 
should be matched to patient ability in employing a device as well as breathing 
pattern (29). For example, pMDIs are easier to use for patient with slow inhalation 
and DPIs match with fast inhalations.  Portability and small size, metered dose 
counter and cost-effectiveness are another factors can be considered when 
choosing amongst different inhalers (18, 35). However patient preference is the 
most significant factor deemed to effect acceptance of the device and success of 
the treatment (18).  
 
1.10. Patient preference 
Therefore, taking into account patient preference will be associated with better 
technique, more adherence and success of treatment. Small et al, (2011) 
evaluated and measured the relation between preference for inhaler devices and 
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treatment outcome. The positive asthma control along with improved quality of 
life was proven after administration of preferred inhalers (66).  
 
While patient preference has not been directly explored with regards to inhaler 
devices, but rather medication management, there have been several studies that 
have reported on patient preference for different inhaler devices used in clinical 
trials. These clinical trials have not focused on patient preference but do give us 
insight into some of the factors, which are important with regards to patient 
preferences. Knowledge gap in terms of patient attitude and perception of 
inhalers necessitates more studies to explore patient acceptance of the devices. 
Majority of studies simply employed questionnaire to explore patient preference 
while qualitative methods are most appropriate for such endeavors. 
 
Table 5 summarises the results from these studies. Clearly, there are factors on a 
variety of different levels, which influence the patient’s preference for one device 
over another. When it comes to patient preference and how it relates to 
satisfaction, there is no data linking the two. Further, there is no evidence to show 
how patient preference and patient satisfaction relate to inhaler technique. We 
can hypothesis that if patients have a preference and are able to choose their 
inhaler, they might be more likely to use it correctly and continue to do so.
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Table 5: Summary of studies about patient preference and inhaler devices  
Study Devices 
used 
Factors influencing preference Preferred 
device 
   
Year Operational use Convenience Oral sensation 
 
 
2004 
(53) 
 
 
 Turbuhaler® 
  pMDI 
 
 Ease of learning to use  
 Ease of holding and operating 
 Ease of knowing when to 
replace 
  Ease of cleaning 
 Comfort with mouthpiece 
 Experience coordination 
problems 
 Rating of accompanying 
instruction 
 Knowledge of how to use 
 the device 
 
 
 Size  
 Shape 
 Durability 
Weight 
 
 
 Unpleasant taste 
 Irritation in the 
mouth 
 Feel of medication 
in the airway 
 
Turbuhaler® 
 
 
2003 
 (67) 
     
  Diskus® 
  pMDI 
 
 Ease of use  
 Easier to be taught 
 Easier to Know how many 
doses are left 
 Ease of cleaning 
 
 
 Convenient to carry 
 Durability 
 
 
N/A 
 
Diskus® 
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Study Devices 
used 
Factors influencing preference Preferred 
device 
 
Year Operational use Convenience Oral sensation 
 
 
2009 
(68) 
 
 
 Turbuhaler® 
 Respimat®              
SMI 
 
 Overall feeling of inhaling 
 Inhaled dose goes to lungs 
 Amount of medication left 
 Works reliably 
  Ease of inhaling a dose 
 Using the inhaler 
 Speed medicine comes out 
 
 
 Instruction for use 
 Size  
 Durability 
 Ease of cleaning 
 Ease of holding 
during the use 
 Convenience of 
carrying 
 
 
N/A 
 
Respimat® 
SMI 
 
 
1998 
(69) 
 
 
Diskus® 
Turbuhaler® 
 
 
 
 Instruction leaflet 
 Ease of holding     
 Overall perceived ease of use 
 Ease of use in acute 
exacerbation  
 Counting mechanism                 
 Ability to use medicine 
quickly  
 Large amount of dosage               
 Ease of use of cap                     
 Overall preference 
 
 
 
 
 
 Shape of mouthpiece 
 Ease of carrying 
around 
 Hygiene of the device 
 Susceptibility to 
moisture Size                               
 Weight                              
 Overall attractiveness 
 
 
 Tasting the medicine  
 
 
 
Turbuhaler® 
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Study Devices 
used 
Factors influencing preference Preferred 
device 
Year Operational use Convenience Oral sensation 
 
1997 
(70) 
 
 
 
Diskus®  
Diskhaler® 
 
 
 Easy to load 
 Easy to hold and 
operate 
 Easy to tell number of 
doses left 
 
 Convenient to carry 
 Durability 
 Easy to clean 
 
N/A 
 
Diskus® 
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1.11. Significance  
 Although it is increasingly taken for granted that patients’ opinions on treatment 
are widely sought (65, 71, 72), little is known about patient preference for inhaler 
devices and its relationship with inhalation technique. The knowledge gap 
regarding inhaler device selection, patient preference and inhaler technique 
should be addressed in future studies (22). The result of this kind of studies will 
deepen our understanding about patient thought of inhalation systems in 
respiratory treatment, also the particular aspects of inhaler device use that are 
important for the patient will be identified. This will have broader implications for 
prescribing of inhaler devices and contribute to the inhaler device development in 
the future.  
 
1.12. Aim and Objectives 
The overall aim of this research was to explore the potential relationship between 
patient choice and patient experiences of inhaler use. 
The objectives of this study are:  
1) Explore the attitudes, perceptions and preferences of people with asthma 
regarding inhaler devices.  
2)   Explore patient’s experience with choosing their inhaler devices. 
3) Explore the relationship between inhaler technique and the attitudes, 
perception and preference of people with asthma regarding inhaler devices. 
 
We hypothesize that taking into account the patient preference and 
attitude toward inhaler devices will lead to acceptance of the device and 
better technique. That is when patient are given a choice in selecting an 
inhaler and prescribed the preferred device; they will demonstrate better 
technique which improves the ultimate treatment outcome. 
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Material and Methods 
 
2.1. Overall design 
In order to gain a deeper understanding of the relationship between inhaler 
technique, patient satisfaction, preference and role of decision-making with 
regards to inhalers, this study took the form of a mixed methods design. Data 
collected through qualitative interview, a quantitative survey and assessment of 
inhaler technique was triangulated.  This research was approved by the University 
of Sydney, Human Research Ethics Committee.  
 
2.2. Participant recruitment 
In order to be eligible for study potential participants were required to be at least 
18 years old, diagnosed with asthma and currently using at least one inhaler 
device for their asthma treatment. Subjects who were unable to speak English, 
were unable to self-complete the questionnaire or did not self-administer their 
inhaler were excluded from study.  
 
Participants were recruited through a convenience sample of community 
pharmacies that have expressed an interest to participate in research. 
Participating pharmacies displayed study advertisements in their pharmacy, 
inviting potential participants to register an interest with their pharmacists. In 
addition, potential participants who presented a prescription for asthma 
medication were approached by their pharmacist and invited to participate. All 
potential participants were referred to the researcher who then explained the 
study and organised a time to conduct the study.. All participants signed informed 
consent prior to enrolling in the study.  
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Following enrolment, a face-to -face interview was conducted with the participant 
in the pharmacy. All interviews were conducted by one researcher (LJ). Following 
the completion of the interview, participants completed the Patient Satisfaction 
and Preference questionnaire (PASAPQ) (73). Participants were then asked to 
demonstrate to the researcher (LJ) how they would usually use their inhaler. This 
allowed the researcher to assess their inhaler technique, based on device-specific 
inhaler checklists (described below).   
 
All participants who completed the study were offered a $30 gift voucher to be 
spent inside the pharmacy as compensation for any inconvenience. 
 
2.3. Sample Size 
As qualitative approach was the main approach of this project, therefore a sample 
size was based on the sample required to reach saturation of data and until the 
generation of data did not result in the identification of any new concepts. This 
occurred within 20 interviews however, data collection continued up to 25 
interviews. 
 
2.4. Data collection 
 
2.4.1. Qualitative data 
A semi-structured interview guide was developed with the aim of exploring the 
participant’s attitudes, perceptions and preferences for their inhalers. The semi-
structured interview guide was developed based on the published literature. Prior 
to development of questions a widespread literature review carried out to address 
all criteria of asthma inhalers and patient point of view regarding their asthma in 
general and inhalers in particular (64, 74, 75). The interviewee’s own vocabularies 
utilized in order to find out new areas without imposing any assumptions (76). 
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After completion of a series of initial interviews some of the questions refined to 
ensure all the targeted domains have been covered in interviews. This was likely 
to occur as little is known about patients’ perception for their inhalers. A summary 
of the key topics addressed and final questions developed and utilized is included 
in Table 6. 
 
Table 6 :Semi-structured interview guide 
Topic  Primary questions Clarification 
1. Background: 
Understanding of 
patient experience and 
perception of inhalers 
and asthma 
management . 
 
 
How is your asthma 
treated? 
What is your opinion 
about your asthma 
management? 
 
Could you take me through the 
medication you are taking for 
your asthma? 
What was your treatment when 
you were first diagnosed? 
How many different devices 
have you used for your asthma? 
How well do you feel your 
medications are controlling your 
asthma? 
Have you ever been admitted to 
the hospital because of asthma 
or a complication of asthma? If 
yes what do you think was the 
main reason for? 
 
 
2. Confidence with 
inhaler and inhalation 
technique. 
How confident are you in 
using your inhaler? 
Who has shown you how to use 
your inhaler in past? How 
helpful was it? 
How do you evaluate your 
inhalation technique? 
 
 
 
3. Perception about 
their role in treatment 
decision- making. 
 
 
 
What is the process for 
deciding on which inhaler 
you will need for your 
asthma? 
 
How much are you involved in 
decisions about your 
treatment? Has this 
involvement changed over the 
time? 
Have you ever given a choice in 
selecting an inhaler? Would this 
be important for you? Why? 
Describe the kind of the role 
you would like to have had? 
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Topic  Primary questions Clarification 
4. Overall views on 
inhaler. 
 
What are your overall 
thoughts about your 
inhaler? 
What do you like or dislike 
about your inhaler? 
Have you ever thought of 
changing the inhaler? 
5. Reasons for 
satisfaction. 
What do you like most 
about your inhaler? 
What do you like/dislike about 
your inhaler? 
Have you ever thought of 
changing your inhaler? 
How difficult/easy is it to use? 
6. Reasons for 
dissatisfaction. 
 
What are your greatest 
concerns about your 
inhaler? 
What makes you to feel you 
have difficulty with your 
inhaler? 
What do you like about the 
operation of your inhaler? 
Have you ever had difficulty to 
operate your inhaler during 
attack? 
7. Identification of an 
ideal inhaler and the 
specific elements that 
make it ideal. 
How would you describe 
your ideal inhaler? 
 
What aspects of an inhaler are 
most important to you and 
why? 
 
 
2.4.2. Patient Satisfaction and Preference Questionnaire (PASAPQ) 
The Patient Satisfaction and Preference Questionnaire (PASAPQ) is a validated 
instrument which measures patient perception and preference for inhaler devices 
(Table 7) (73). It is validated for 5 domains (satisfaction with performance, 
satisfaction with convenience, overall satisfaction, preference for device and 
willingness to continue to use a device). The preference sub-scale in this 
questionnaire was primarily designed to measure patient preference when two 
inhalers are compared. It clearly states: Which inhaler do you prefer? a) Inhaler one 
b) Inhaler two c) No preference.  This study was aimed to gain an understanding of 
patients’ opinion for asthma inhalers rather than comparing inhalers. Therefore not 
all participants were using more than one inhaler. For the purposes of this 
research, only the former three domains are relevant. As a result,  only these three 
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were used in this research. The 3 domains are covered in 14 items of the PASAPQ 
and relate to the following three sub-domains: satisfaction with performance (7 
items), satisfaction with convenience (6 items) and overall satisfaction (1 item). For 
each item within the three sub-domains, a 7 point Likert type response scale is 
utilized (68, 73). It is designed for self-administration.  
 
Table 7: Relevant Patient Satisfaction and Preference Questionnaire domains (73) 
Domain Question Description  
 
Scoring 
To
ta
l s
co
re
 
P
er
fo
rm
an
ce
 d
o
m
ai
n
 
Q1 Overall feeling of inhaling 
 
 
 
 
All items scored on a 
7-point Likert scale: 
 1= Very dissatisfied 
2=Dissatisfied 
3=Somewhat 
dissatisfied 
4=Neither satisfied 
nor dissatisfied 
5=Somewhat satisfied 
6=Satisfied 
7=Very satisfied 
Q2 Inhaled dose goes to lungs 
Q3 Amount of medication left 
Q4 Works reliably  
Q5 Ease of inhaling a dose 
Q10 Using the inhaler 
Q11 Speed medication comes out 
C
o
n
ve
n
ie
n
ce
 d
o
m
ai
n
 
Q6 Instruction for use 
Q7 Size of the inhaler 
Q8 Durability of the inhaler 
Q9 Ease of cleaning inhaler 
Q12 Ease of holding during use 
Q13 Convenience of carrying 
Q14 Overall satisfaction  
 
 
2.4.3. Inhalation Technique assessment 
Inhaler technique checklists were utilized to assess inhaler technique (Tables 8 – 
12).  These checklists were developed from manufacturer developed written 
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inhaler devices instructions through an Australian Research Council grant LP 
0882737.  
Participants were asked to demonstrate how they would usually use their inhaler. 
This technique was compared to the items (steps) listed in the checklist. A 
participant was assessed as having “correct” technique only if they were able to 
perform all steps listed in the checklist correctly. Tables 8 to 12 are samples of the 
checklist used. 
 
Table 8: Inhaler technique assessment checklist for Accuhaler® 
 Accuhaler® 
1.   Open Inhaler.  
2.   Push lever back completely to load dose. 
3.   Exhale all air out of lungs. 
4.   Exhale away from the mouthpiece. 
5.   Hold inhaler horizontally. 
6.   Place mouthpiece between teeth and seal with lips. 
7.   Inhale slowly and deeply. 
8.   Hold breath for as long as is comfortable (aim for 10 seconds). 
9.   Exhale away from the inhaler. 
10. Close Inhaler. 
 
Table 9: Inhaler technique assessment checklist for Turbuhaler® 
Turbuhaler® 
1.   Unscrew and remove the cap from the inhaler. 
2.   Keep inhaler upright. 
3.   Rotate grip one way, then back, to load dose. 
4.   Exhale all air out of lungs. 
5.   Exhale away from the mouthpiece. 
6.   Keep head upright, lift chin slightly. 
7.   Place mouthpiece between teeth and seal with lips. 
8.   Inhale forcefully and deeply.  
9.   Pause, then breathe out normally. 
10. Exhale away from the inhaler.   
11. Replace cap. 
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Table 10: Inhaler technique assessment checklist for Pressurised Metered Dose 
Inhaler 
Pressurised Metered Dose Inhaler 
1. Remove mouthpiece cover and shake well. 
2. Exhale all air out of lungs.  
3. Keep head upright, lift chin slightly. 
4. Mouthpiece between teeth and seal with lips. 
5. Inhale slowly and press canister early. 
6. Continue slow and deep inhalation. 
7. Hold breath for as long as is comfortable (aim for 10 seconds). 
8. Breathe out normally, away from the inhaler. 
9. Replace cap. 
 
Table 11: Inhaler technique assessment checklist for Pressurised Metered Dose 
Inhaler with Spacer 
Pressurised Metered Dose Inhaler + Spacer 
Single Breath Technique Method  
1. Assemble the spacer. 
2. Remove mouthpiece cover of inhaler, shake and insert into spacer. 
3. Exhale all air out of lungs. 
4. Keep head upright, lift chin slightly. 
5. Spacer mouthpiece between teeth and seal with lips. 
6. Press canister and inhale slowly and deeply from spacer. 
7. Hold breath for as long as is comfortable (aim for 10 seconds). 
8. Breathe out normally. 
 
Multiple Breath Technique Method  
1. Assemble the spacer. 
2. Remove mouthpiece cover of inhaler, shake and insert into spacer. 
3. Exhale all air out of lungs. 
4. Keep head upright, lift chin slightly. 
5. Spacer mouthpiece between teeth and seal with lips. 
6. Breathe in and out of spacer, then press canister. 
7. Continue to breathe normally through spacer for a few breaths.  
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Table 12: Inhaler technique assessment checklist for Autohaler® 
Autohaler® 
1.   Remove inhaler cap and shake well. 
2.   Raise lever up to prepare device.     
3.   Exhale all air out of lungs.    
4.   Keep head upright, lift chin slightly. 
5.   Place mouthpiece between teeth and seal with lips. 
6.   Inhale slowly and deeply. 
7.   Hold breath for as long as comfortable (aim for 10 seconds). 
8.   Breathe out normally away from inhaler. 
9.  Push lever down and replace cap. 
 
 
2.5. Analysis of data 
 
2.5.1. Qualitative analysis 
Analysis performed by two researchers independently and agreement on results 
achieved prior to finalisation of themes and concepts. 
Interviews were audio recorded and transcribed verbatim. Analysis involved 
content analysis of the transcripts to identify emerging themes and concepts. The 
reduction of mass of data into categories carried out by means of coding. Open 
coding was the first step in putting data in categories and subcategories and 
generates initial labels. Then further coding initial labels and themes reviewed 
which led to emergence of new concepts and themes and finally the overall 
analysis organised to measure the core concept (77). 
 
2.5.2. PASAPQ analysis 
Each participant received a total score for the sub-domains of satisfaction with 
performance, satisfaction with convenience and overall satisfaction.  
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For the “satisfaction with performance” score, the value of each of the 7 
performance questions was added. As these questions were based on a 7-point 
Likert scale, each participant obtained a value between 7 and 49. 
For the “satisfaction with convenience” score, the value to each of the 6 
performance questions was added. As these questions were based on a 7-point 
Likert scale, each participant obtained a value between 6 and 42. 
For the “overall satisfaction” score, as there was only one question addressing this 
domain, participants received a value between 1 and 7.  
 
PASAPQ scores were analysed descriptively. Based on the findings of Kozma et al 
(73) a difference of 3 to 4 points is required to observe a small difference and 8 to 
10 points to observe a medium difference in the convenience and performance 
domains. In the current study, a difference of 8 to 10 points was adopted to 
represent a significant difference in the convenience and performance domains 
respectively. 
 
2.5.3. Inhalation technique assessment 
For each inhaler, participants were evaluated as having either correct (performed 
all steps correctly) or incorrect (did not perform all steps correctly) technique. In 
addition, to identify whether participants were able to use their inhalers correctly, 
they received an “inhaler technique score”. This corresponded to the number of 
steps performed correctly.   
 
2.5.4. Convergence/Triangulation of data 
In order to describe any pattern of association between participants point of view 
from qualitative interview with inhalation technique result and PASAPQ scores, data 
relating to correct use of inhaler and incorrect use of inhaler, satisfaction with 
performance, satisfaction with convenience and overall satisfaction were 
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triangulated with qualitative responses (exploring preference, and decision-making). 
This was achieved by mapping this data in a matrix. The matrix was then 
qualitatively explored to identify characteristics which could indicate a relationship 
between inhaler technique, satisfaction, preference and decision-making.
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Results 
 
3.1. Demographic information 
Twenty five participants completed the study. A total of 4 different types of 
inhalers were used overall (participants including pMDI, Turbuhaler®, Accuhaler® 
and Autohaler®). The most commonly used devices were the pMDI, Turbuhaler® 
and Accuhaler® with 92%, 32% and 20% of participants using each of these 
respectively. The average number of years of asthma duration was 24.12(±10.4) 
years. Table 13 is a summary of demographic data. 
 
                       Table 13: Subjects demographic information (Total =25) 
Age (years), mean (SD) 
Range  
43.08 (15.5) 
21-79 (years) 
Female, n (%) 19 (76) 
Highest level of education, n (%)  
 
Secondary school 
Diploma or TAFE degrees 
University undergraduate 
Postgraduate degrees 
 
 
 
7 (28) 
8 (32) 
4 (16) 
6 (24) 
Duration of asthma (years), mean 
(±SD) 
Range 
 
24.12 (±10.4) 
2-40 (years) 
Duration of pMDI use (years), mean 
(±SD) 
Range 
 
20.45 (±11) 
2-36 (years) 
Duration of Turbuhaler® use (years), 
mean (±SD) 
Range 
11.06 (±12.1) 
0.5-36 (years) 
Duration of Accuhaler® use (years), 
mean (±SD)  
Range 
 
12.20 (±8.9) 
3-23 (years) 
Duration of Autohaler® use (years) 
(±SD) 
Range 
 
 10 (n=1)  
 N/A (n=1) 
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3.2. Qualitative interviews  
The following themes emerged: Asthma inhalers and expectations, inhaler 
preference, characteristics of an ideal inhaler, Perceived effectiveness of inhalers, 
inhalers and patient decision-making 
 
Asthma inhalers and expectations  
When it came into inhalers as delivery devices, a majority of participants could not 
distinguish between inhaler devices and actual medication in the devices. Inhalers 
from their point of view were part of the treatment process regardless of the type 
of device. It was very difficult to realize the concept of effectiveness from their 
viewpoint whether it is related to device or drug itself. Lack of clear understanding 
of inhalers as mechanical delivery devices was noticeable. In addition, effectiveness 
of medication in relieving asthma symptoms was considered as a sign of good 
inhalation technique. They did not consider that the way in which they used their 
inhaler was an issue here. 
  
Examples of participants’ responses: 
“I like my inhaler, yeah that’s fine. It works very well.” 
(pMDI)(Participant 14) 
 
“I think my technique is pretty good. Because I have just known 
that, all of my bests for certain amount of time and it’s quite 
good. I think my technique is fine. The Ventolin® fixes me up 
every time in a minute.” (Participant 18) 
 
“I am getting results and for me the result is this, my 
asthma decline, my breathing is easier and also if I have 
got some sort of congestion, it releases the congestion 
and actually clears my lungs...because it works, my 
technique must be good.”(Participant 13) 
 
Participants presented various perceptions and opinions in regards to their inhaler 
devices and asthma management. Presented perceptions covered their feeling and 
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expectations of inhaler as delivery devices of asthma medication, which was closely 
linked, to their perceptions of their asthma.  
 
Participants commonly reported being dependent on their inhalers, and the 
discomforted/concern felt being without them when they were needed. In 
reflecting this participants mentioned their desire to be free of asthma and not 
needing to carry their inhalers with them. This rendered the inhalers as a burden. 
They did not distinguish this with regards to the different inhalers. 
 
Examples of participants’ responses: 
 “I would not be without it; I am very dependent on it. I would 
not go anywhere. I go anywhere and I do not have it, I will be a 
bit nervous”. (Participant 22) 
 
“I just feel like one day they are not going to help me. That 
always worries me. You know like they are helping me now but 
are they always going to help me that is my biggest worry, you 
know.” (Participant 16) 
 
“My greatest concern is that I have to use it for rest of my life.” 
(Participant 7) 
 
“I do not think I like much about it. I suppose if I didn’t have 
exertion asthma, I would not use it but it is there, a necessity.” 
(Participant 18) 
 
When talking about their inhalers it was clear that actual medication-related factors 
were influencing patient’s opinion of asthma inhalers. For example, prior 
experience of side effects of asthma medication and reported ineffectiveness of a 
particular medication, affected overall thoughts about their devices. This was 
contrasted with their “experience” with particular “devices” in that long-term use 
of a particular device resulted in satisfaction with the device and perceptions of 
ease of use. 
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Examples of participants’ responses: 
 “I have been trying different things and then I end up using this 
one.  Before I had Pulmicort®. It was not good either. They all 
have something that I get anxiety reactions.” (Participant 23) 
 
“I have used it all my life so very comfortable with it. I know how 
to use it.” (Participants 25) 
 
Another remarkable point-of-view was participants’ lack of interest for new 
inhalers. Although some presented dissatisfaction with some aspects of their 
inhalers, such as a lack of counter for the metered dose inhaler, they lacked 
knowledge and information about alternate inhalers, therefore did not consider 
them as options for treatment. For others effectiveness of inhaler in relieving 
asthma symptoms was adequate to convince them that they did not need to 
change inhalers.  
 
Examples of participants’ responses: 
 “You can feel the benefit of it which is important. So I really 
don’t want to change it, you know. If I am getting comfort and 
relief from that, I think that is the main thing.” (Participant 24) 
 
“I wouldn’t know what to change it to. That is the thing; I have 
only been given the information I have. I have just used what I 
have had, the same sort of inhalers for these years and it has 
worked very well so I have never thought about changing or 
what options are available.” (Participant 14) 
 
“I don’t know what else is available.” (Participant 6) 
  
Inhaler Preference 
Participants with various inhalers presented diverse perceptions and expectations 
of their inhalers based on perceived performance and convenience of use.  
All participants wanted a device that was easy to use and majority expressed 
satisfaction with the ease of use of their inhalers. Some devices were perceived to 
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be easier to use than others. Users of pMDIs perceived that they were easy to use, 
while for some of those using the pMDIs as well as DPIs they felt use was confusing 
and complicated. Participants reported that loading the dose was the most 
troublesome and confusing step with the DPIs. 
 
Examples of participants’ response: 
“I twisted it once and if I am not thinking what I am doing or I go 
away, I think oh have I loaded it? I never know whether I loaded 
it or not and I can be doing this and I don’t know whether I am 
wasting it and it is expensive very expensive so I don’t look at the 
counter you know. I guess it is just a kind of thing I have to pay 
more attention at the time”. (Turbuhaler®)(Participant 22) 
 
“I sometimes just forget which way I have turned it to 
activate it. You have to suck really hard to try to make 
sure you get the gas or whatever is inside which I found a 
bit irritating.”(Turbuhaler®)(Participant 14)   
 
“I did not want to take the other one, what it called the puffer 
inhaler yeah I didn’t really like to take that one and I just found it 
really too hard to use it permanently. It may work for a couple of 
seconds but then I struggle to breathe again so I found it very 
difficult to use. It wasn’t effective.” (pMDI)(Participant 8) 
 
“It is very simple. You just puff it and breath it in so it’s pretty 
simple which is what I like (pMDI).” (Participant 14) 
 
In addition, some participants expressed concerns about the difficulty of inhaling a 
dose from a DPI when you had difficulty breathing properly during an attack.  
 
Examples of participants’ response: 
“Sometimes tough if you are suffering from asthma, you 
can’t take a deep breath to inhale really deeply. With a 
good inhaler you have get a take a normal breath and it 
just goes in.” (Turbuhaler®)(Participant 20) 
 
“I found that a little bit more pain to use it. Having to suck in 
because my breath control isn’t that great but using the puffers 
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are pretty straightforward, it’s always helped.” (Turbuhaler®) 
(Participant 14) 
 
An aspect that was important to participants was the ability to identify how much 
drug was left in the device once use commenced. Participants particularly liked the 
dose counter on dry powder inhalers while pressurised metered dose inhalers 
specifically Ventolin® still does not have a counter. Lack of dose counter was one 
of the main concerns due to shortage of medication in emergency events. 
 
Examples of participants’ response: 
“I can see the numbers that how many I have left. In that way I 
know that I can go and get a new one.” (Accuhaler®) 
(Participant 23) 
 
“I quite like the way that some of them now have the little 
numbers on it, so I know when it runs out instead of keep trying, 
when you realize that there is actually nothing left into it.” 
(pMDI) (Participant 17) 
 
“I don’t like Ventolin® not being able to complete tell them when 
it runs out. But that getting down to little half things, dose 
counter would be better”. (Participant 3) 
 
Another important feature was convenience: portability and size. Participants felt 
that the smaller size inhalers are linked to improved compliance to medication due 
to the convenience of carrying inhaler in handbag or pocket. However, what was 
convenient for one participant was not necessarily the case for others. For 
example, although for some the inhalers were considered bulky and difficult to fit 
in a pocket or handbag, others found them portable and easy to carry around.  
 
 
 
Examples of participants’ response: 
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“They are small, easy to take with me. I put them in my hand bag 
yeah.” (pMDI, Turbuhaler®)(Participant 10) 
“It is easy to carry around. I travel quite a bit for work so it is not 
a big thing to carry around.” (Turbuhaler®)(Participant 25) 
 
 “Size is all right. It is just always in my pocket here so yeah 
pretty much just like, it is just something you have it. It is just 
there.” (pMDI) (Participant 20) 
 
“Maybe the size, which is when I am going out if I need it, I have 
a big bag. When I need to go out with a smaller handbag I tend 
to leave it at home just because of the size” (Accuhaler®). 
(Participant 9) 
 
 “The size at the Seretide® is probably is bigger than I would have 
liked.” (Accuhaler®)(Participant 3) 
 
 “It is bulky fit not into your pocket when you go for a walk. That 
is you get to bring your bag if you have a small bag or whatever. 
That is down side to it. I am not sure they could do anything 
smaller or slimmer, I don’t know but if they could do it the same 
thing in the smaller container.” (pMDI)(Participant 22) 
 
“The only thing I guess could be smaller because these days 
when you wear I suppose skinny jeans and things like that; it is 
just big it’s never got the small”. (pMDI)(Participant 18) 
 
In addition, participants have the same opinion concerning their inhalers to be 
hygienic to use. Inhalers are used on a daily basis and carried in handbags and 
pockets. Participants recognized that dust can build up in mouthpiece and it may 
aggravate asthma while inhaling a dose. Cleaning inhalers on a regular basis was 
found inconvenient by consumers and they presented dissatisfaction about inhalers 
hygiene in general and pMDIs in particular. While DPIs are preferred in terms of 
hygiene, they raised concern of how pMDIs lids came off easily and dust could build 
up in the nozzle. 
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Examples of participants’ response: 
“What I dislike is when I thrown them in my bag and something 
get caught in them and I go to use it and it goes to my lung… 
Things can go down inside it or if I lost the cap on the end, lots of 
funny things end up from my handbag in there then end up down 
in my lungs.” (pMDI) (Participant 17) 
 
“Turbuhaler® is more contained than the pump in terms of if you 
have a pump in your backpack or your pocket or wherever, can 
get dirt inside. The mechanism those that Turbuhaler® is quite 
contained and clean ... I guess if you got dust in your inhaler, it’s 
one of the triggers for asthma then perhaps it’s important”. 
(Participant 6) 
 
“What do I like most about it is just the fact that it has got the 
mouthpiece covered up. I quite like that so this is sort of thing 
not really you think, but the hygiene fact to it. That would be the 
positive thing.” (Accuhaler®)(Participant 13) 
 
Additionally participants noted the cost of asthma medications, specifically 
preventers. They were found to be expensive. 
 
Examples of participants’ response: 
“I never know whether I loaded it or not and I can be doing this 
and I don’t know whether I am wasting it and it is expensive very 
expensive.” (Turbuhaler®)(Participant 22) 
 
”Seretide®, it’s a bit expensive I mean the government subsidized 
it so it’s $32 or $34.20 now so it’s a bit on the expensive side… 
You can just get that one [Ventolin®] whenever you want it is out 
of script. That’s really handy but with Seretide® you have to go 
to doctor and get a script which is annoying cause he charges for 
it, so it’s a bit expensive.”(Participant 7) 
 
 
 
 
Characteristics of an ideal inhaler 
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Some participants had never thought about what they wanted in an ideal inhaler 
while others had clear opinions. Characteristic of an ideal inhaler from their point of 
view was a reflection of preferred features of inhaler devices, whether their own 
inhalers meets the preference or not. These opinions were based on performance 
and convenience. Due to the importance of compliance to inhalers as daily 
medication, ease of use was the dominant feature of a preferred inhaler. Ease of 
use was particularly important during emergency treatment. Participants reported 
that ease of use make an inhaler quick enough to relieve the asthma attack. In 
addition, the dose counter was another advantage to an inhaler to overcome the 
concern of 
running out the medication. Majority believed that a dose counter should be an 
integral part of an inhaler. 
 
Examples of participants’ response: 
 “Easy to use... compliance because you have something you 
have to take it, particularly the steroid ones. So it’s the 
compliance things. If it is too hard, you do not take it and also 
just trying to remember to take it, linking that to something you 
do like brushing your teeth.” (Participant 13) 
 
 “Gauge on the Ventolin® would be a big advantage ... I wouldn’t 
like to be caught up without having something in the inhaler. 
Because I do not know whether you are asthmatic, but its worse 
feeling when you cannot breathe. Even to get one puff is 
something when you can feel that, it is giving you some relief so 
I would like the one show it.” (Participant 24) 
 
Getting feedback after correct use was the preferred aspect of some of inhaler. 
The idea of being able to monitor the delivery of the medication was raised and 
discussed. That is, participants expressed a preference for an inhaler that shows 
you the delivery of the medication to the lungs. 
 
Example of participants’ response: 
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 “If there was a way of monitoring the delivery of medication 
that wouldn’t be a bad feature to have as well, just in terms of 
making ensuring.... For the people who have to monitor their 
asthma very carefully, method of monitoring the delivery of the 
medication would be useful to have as well.” (Participant 25) 
 
With regards to convenience, the majority of participants were agreed that the 
significance of portability and small size of an inhaler and how it would affect the 
compliance. In addition, ease of cleaning and the hygiene of an inhaler were 
emphasized as an important feature.  
 
Examples of participants’ response: 
“It would be lighter and smaller, the portability reasons.” 
(Participant 1) 
 
“Keep it clean so nothing would get it on top of it.” (Participant 
12)  
 
Perceived effectiveness of inhalers  
Majority of participants were confident about their inhalation technique and found 
inhalers very easy to use. Their confidence was related to the effectiveness of the 
medication rather than any objective measure of whether they could use them 
correctly. Participants believed their effective asthma control is the best indicator 
of good inhalation technique.   
 
Examples of participants’ response: 
“I am getting results and for me the result is the asthma 
declines, my breathing is easier and also if I have got some sort 
of congestion, it releases the congestion and actually enables me 
to clear the lungs... because it works my technique must be 
good.” (Participant 13) 
 
“Whether I am getting the full dose I am not sure but certainly in 
terms of its effects, it seems to work well and I do not have an 
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asthma attack for a long time so I have got no reason to doubt 
that I am not doing it correctly.” (Turbuhaler®)(Participant 25) 
 
In addition, the fact that many of the participants had used their inhalers for a long 
time made them confident that they were using them correctly. 
 
Examples of participants’ response: 
 “Confident. I have been using them in all my life so it’s like 
blinking.”(Participant 20) 
 
“It is something I have used probably for about 10 years so yes 
very confident. My technique is effective.” (Participant 12) 
 
History of technique training, perceived ease of use, feeling taste of medication and 
doctors’ satisfaction of technique were all various reasons associated to patient 
confidence of technique. Majority of participants had received training from their 
doctor and emphasized the significance of proper training with an educated person. 
 
Examples of participants’ response: 
“I use it in the right way. The way the doctor showed me.” 
(Participant 23) 
 
 “It is pretty much; I mean it’s not like a science. Is it? Yeah open 
your mouth and put your head back and take a couple of puffs 
and pretty much, if I can do it, anyone can do it.” (Participant 20) 
 
“I did it in front of the doctor and the doctor showed me. He 
wanted to see how I take it, to see if I am in bad condition, and 
he said that you are doing in the right way. He was happy so I 
was happy.” (Participant 16) 
 
“Doctors have never complained. I don’t see it is coming back 
out of my mouth when I use it or is coming out of the top of 
puffer so I assume its ok.” (Participant 17)  
 
 “I usually get the taste. I can taste the medication ... Yeah it has 
a certain taste.” (Participant 11) 
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 “Helpful [doctor demonstration] because probably you wouldn’t 
ever read the instruction. My dad had the same, had Symbicort® 
as well, he clicked it once and expected it to work and 
complained how it didn’t work and I told him you have to click it 
twice and the third time it works so I am glad yeah I am glad 
that he told me.” (Participant 8) 
 
Only three participants expressed uncertainty about their inhaler technique 
although they found asthma treatment effective. 
 
Examples of participants’ response: 
“I am not sure if I am using them in the right way but yeah it is 
working.” (Participant 9) 
 
“I don’t mind using the inhalers. I can manage it pretty well. I 
prefer using the spacer because I don’t think I’ll be comfortable 
just using inhaler by itself with my technique, so that’s why I use 
it with the spacer.” (Participant 7) 
 
Inhalers and patient decision-making  
Almost none of the participants had been informed about the possibility of being 
involved in treatment decision-making. They did not express dissatisfaction with 
this. No involvement in decision-making was not their concern when the outcome 
of good asthma control was fulfilling. A strong relationship with their doctor which 
was based on trust was adequate to build up satisfaction with the doctor’s decision. 
In addition, health care professionals’ education had convinced them to use their 
knowledge in management of their health condition. 
 
 
 
 
Examples of participants’ response:  
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“No, I have always got the one doctor says, the doctor says take 
that I will take that. I don’t take away from that because I trust 
them after years.” (Participant 21) 
 
“I was just thinking, I would take the advice of my doctor 
because he has an educated opinion.” (Participant 18) 
 
Participants thought that treatment decision-making was influenced by the 
necessity for good asthma control, based on patient asthma history rather than 
considerations of the device. Participants felt that the final goal of asthma 
treatment was asthma control and did not think that inhaler device selection 
played any significant role in that. In some cases development of side effects to 
specific ingredients were thought to lead to changes in the treatment regimen but 
still not with any consideration of the actual inhaler device or inhaler technique.  
 
Examples of participants’ response: 
“The sort of the device I use is not that important to me, it is the 
effect has on me and the management of my condition is more 
important than how it is administered.” (Participant 25) 
 
“It is not about the method of delivery for me. It’s about 
delivery. It’s about what medication does.” (Participant 13) 
 
On the other hand, a minority of participants mentioned amendment to therapy or 
preference for a specific inhaler due to lack of proper technique.   
 
Examples of participants’ response: 
 “Ventolin®, I just wasn’t getting any benefit from it because I 
couldn’t take it, I couldn’t breathing at the right time and I found 
it really uncomfortable to use and they told me Symbicort® they 
give to children so I told Ok I’ll try that one and because it is very 
mild and it’s just exercise induced asthma then I don’t need 
anything stronger.” (Participant 8) 
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When it came to decision-making, a minority of participants expressed a preference 
for being involved in treatment decision-making. Most were content with the 
prescribers’ recommendations.  
 
Examples of participants’ response: 
“Prefer to do what I like than what they like.” (Participant 3) 
 
“That would be good, if they said to me which one do I prefer I 
go for the puffer just one click done. With other ones you got a 
maneuver it with your hands. Why is that? Why I am not able to 
saying that?” (Participant 22) 
 
3.3. Inhalation technique 
Participants were on various inhalers for their asthma treatment. Some 
participants used their pMDI with a spacer with single breath technique and 
multiple breath technique. A number of some participants used more than 1 
device. A maximum of 3 devices was used by one individual. Table 14 summarizes 
the number of participants using each device and the proportion of participants 
demonstrating correct technique for each device. 
 
Table 14: Proportion of participants demonstrating correct technique  
Device 
Number of 
participants using 
this inhaler 
Proportion 
demonstrating 
correct technique (%) 
pMDI 22 9 
pMDI+ Spacer single  
breath technique 
3 33 
pMDI+ Spacer 
multiple 
 breath technique 
1 0 
Turbuhaler® 8 0 
Accuhaler® 5 40 
Autohaler® 1 0 
Note: Amongst the 25 participants a total of 40 inhalers were used. Proportion relates to 
proportion of participants using a particular device.                              
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3.4. PASAPQ  
Mean (±SD) PASAPQ scores for satisfaction with performance, satisfaction with 
convenience and overall satisfaction were 41.43 (±6.2), 34.67 (±4.9) and 6 (±0.8) 
respectively. 
Table 15 is a summary of the mean scores for PASAPQ score for satisfaction with 
performance, satisfaction with convenience and overall satisfaction in regards to 
different devices. Only one participant had Autohaler®, as a result the mean score 
was not calculated for Autohaler®. 
 
Table 15: Patient Satisfaction and Preference Questionnaire (PASAPQ) score for 
satisfaction with performance, convenience and overall satisfaction for each 
device 
PASAPQ scores pMDI (n=23) Turbuhaler®(n=8) Accuhaler® (n=5) 
Mean(SD) Mean(SD) Mean(SD) 
Satisfaction  with 
performance  
scoresa 
41.84(±5.4) 
 
40.25 (±6.4) 
 
40.2 (±9.8) 
 
Satisfaction with 
convenience 
scoresb 
    34.39 (±4.8) 
 
36.50 (±4.1) 
 
 
31.8 (±5.9) 
 
  
Overall 
satisfaction with 
inhalerc 
 
 
 
6.13 (±0.8) 
 
 
 
 
6.12 (±0.9) 
 
 
 
 
5.60 (±1.1) 
 
 
a
For satisfaction with performance score, minimum is 7 and maximum is 49. Scores ≥ 35 indicates at least 
“somewhat satisfied”. 
b
For satisfaction with convenience score, minimum is 6 and maximum is 42. Scores ≥ 30 indicates at least 
“somewhat satisfied”. 
c
For overall satisfaction score, minimum is 1 and maximum is 7. Scores ≥ 5 indicates at least “somewhat 
satisfied”. 
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3.5. Triangulation 
Table 16 summarizes the mean (±SD) score for satisfaction with performance, 
satisfaction with convenience and overall satisfaction relating to correct use of 
inhaler and incorrect use of inhaler. 
 
Table 16: Mean PASAPQ scores for performance, convenience and overall 
satisfaction in regards to correct use of inhaler and incorrect use of inhaler 
Inhalation  
technique result 
 
Satisfaction with 
Performancea 
Satisfaction with  
Convenienceb 
Overall  
Satisfactionc 
Mean (±SD) 
 
Mean (±SD) 
 
Mean (±SD) 
 
Correct  
 
40.00 (±7.7) 
 
31.50 (±4.9) 
 
6.00(±0.8) 
Incorrect  
 
41.60 (±6.1) 
 
35.12(±4.8) 
 
6.09 (±0.9) 
 
a
For satisfaction with performance score, minimum is 7 and maximum is 49. Scores over 35 indicates at least 
“somewhat satisfied”. 
b
For satisfaction with convenience score, minimum is 6 and maximum is 42. Scores over 30 indicates at least 
“somewhat satisfied”. 
c
For overall satisfaction score, minimum is 1 and maximum is 7. Scores over 5 indicates at least “somewhat 
satisfied”. 
 
Matrix A (Table 17) represents the data relating to satisfaction with performance, 
satisfaction with convenience and overall satisfaction from PASAPQ triangulated 
with qualitative responses (exploring preference, and decision-making) for 
participants with correct inhalation technique. 
Matrix B (Table 18) represents the data relating to satisfaction with performance, 
satisfaction with convenience and overall satisfaction from PASAPQ triangulated 
with qualitative responses (exploring preference, and decision-making) for 
participants with incorrect inhalation technique. 
 
Triangulation of data did not uncover a relationship between inhaler tehcnique, 
saitsfaction, perception of inhaler devices and or the opportunity for participants to 
have a choice in device selection. However there appeared to be an association 
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with correct inhaler technique and participants who were more aware of their 
asthma and expressed motivation to achieve optimal control. This trend was seen 
through the relative qualitative data when separated for the particpatns with 
correct versus incorrect technique. PASAPQ scores and qualitative feedback relating  
to satisfation were consistent.
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Table 17: Matrix A of triangulation for participant with correct technique relating to score from PASAPQ and qualitative 
feedback 
Participant Inhalation 
technique 
PASAPQ score Qualitative feedback 
Operation  Convenience Overall 
satisfaction 
P4 
Correct 
(MDIand  
MDI+ Spacer) 
41 34 6 
 Effectiveness of medication leads to satisfaction with 
inhalers 
 Satisfaction with asthma management and satisfaction 
with inhalers 
 Some level of choice 
 Asthma control was important 
P13 
 
Correct (MDI) 
40 29 6 
 Confidence about technique because of effectiveness of 
medication 
 Asthma control more important than type of inhaler 
 No involvement in treatment decision making 
Correct 
(Accuhaler®) 
30 26 5 
P21a 
Correct 
(Accuhaler®) 
49 37 7 
 Overall dissatisfaction with asthma and medication lead to 
dissatisfaction with inhalers 
 Concern of taking medication and having asthma 
 Confidence about technique because of effectiveness of 
medication 
 Could not distinguish device from medication 
 No involvement in treatment decision making 
a
Participant had 2 different inhaler and demonstrated correct technique for one of them and incorrect technique for other one. 
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Table 18: Matrix B of triangulation for participants with incorrect technique relating to scores from PASAPQ and qualitative 
feedback 
Participant Inhalation 
technique 
PASAPQ score Qualitative feedback 
Operation Convenience Overall 
satisfaction 
 
P1 
Incorrect 
(MDI) 
33 28 6 
 Overall satisfaction with inhalers 
 Long term usage leads to satisfaction 
 Confidence of technique 
 
P2 
 
Incorrect 
(MDI) 
44 32 5 
 Overall satisfaction with inhalers 
 Confidence of technique 
 
 
P3 
 
Incorrect 
(MDI) 
31 29 6 
 Effectiveness leads to satisfaction with inhalers 
 Effectiveness of medication leads to confidence of 
technique 
 Satisfaction with ease of use 
 Confidence of technique 
Incorrect 
(Accuhaler®) 
 
29 25 4 
 
 
P5 
 
Incorrect 
(MDI) 
35 40 7 
 Effectiveness of medication leads to confidence with 
technique 
 Difficult operation is a reason of dissatisfaction with 
device 
 Actual medication influences overall opinion of inhalers 
 Confident of technique with Autohaler® 
Incorrect 
(Autohaler®) 
48 41 7 
 
 
P6 
 
Incorrect 
(MDI) 
45 33 6 
 Could not distinguish device from medication 
 Confidence with technique 
 Actual medication influences overall opinion of inhalers 
 Satisfaction with convenience of Turbuhaler® 
 No involvement in treatment decision making 
Incorrect 
(Turbuhaler®) 
45 40 7 
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Participant Inhalation 
technique 
PASAPQ score  Qualitative feedback 
Operation Convenience Overall 
satisfaction 
P7 
Incorrect 
(MDI+ 
Spacer) 
40 28 
4 
 
 
 
 
 
 
 Not confident of technique without spacer 
 Overall dissatisfaction of having asthma and necessity of 
using inhalers 
 Dissatisfaction with convenience of device 
 Actual medication influences overall opinion of device 
 No involvement of treatment decision making 
P8 
Incorrect 
(Turbuhaler®) 
47 39 7 
 Effectiveness of medication leads to satisfaction with 
inhaler 
 Effectiveness of medication leads to confidence with 
technique 
 Satisfaction with inhaler because of easy performance 
 Some level of involvement in treatment decision making 
P9 
 
Incorrect 
(MDI) 
49 32 6 
 Not very confident about technique 
 Effectiveness of medication leads to some level of 
confidence about technique 
 No involvement in treatment decision making 
 
Incorrect 
(Accuhaler®) 
48 34 6 
       P10 
 
Incorrect 
(MDI) 
 
41 36 6 
 Effectiveness of medication leads to satisfaction with 
inhaler 
 Could not distinguish medication from device 
 Dissatisfaction with operation of Turbuhaler® /Non 
confident about technique 
 Confidence of technique with MDI® because of ease of 
use 
Incorrect 
(Turbuhaler®) 
 
 
28 28 6 
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Participant Inhalation 
technique 
PASAPQ score  Qualitative feedback 
Operation Convenience Overall 
satisfaction 
P11 
Incorrect 
(MDI) 
33 29 5 
 Long term usage leads to confidence about technique 
 Could not distinguish device from medication 
 Effectiveness is the most important inhaler feature 
 Effectiveness of medication leads to satisfaction with 
inhaler 
 
Incorrect 
(Turbuhaler®) 
40 33 6 
P12 
Incorrect 
(MDI) 
46 39 7 
 Long term usage leads to confidence about technique 
 Satisfied with operation of inhaler 
P14 
Incorrect 
(MDI) 
47 38 7 
 Effectiveness of medication and long term usage lead to 
satisfaction with inhaler 
 Long term usage leads to confidence about technique 
 Effectiveness of medication leads to confidence about 
technique 
 Satisfaction with operation leads to confidence about 
technique 
 Could not distinguish device from medication 
P15 
Incorrect 
(MDI) 
45 39 6 
 Long term usage leads to satisfaction  
 Effectiveness of medication leads to confidence about 
technique 
 Overall satisfaction with inhalers 
 Could not distinguish medication from device 
P16 
Incorrect 
(MDI and 
MDI+ Spacer) 
38 35 6 
 Confidence about inhalation technique 
 Effectiveness of medication leads to satisfaction with 
inhaler 
 Satisfaction with operation leads to satisfaction with 
inhaler 
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Participant Inhalation 
technique 
PASAPQ score  Qualitative feedback 
Operation Convenience Overall 
satisfaction 
P17 
 
Incorrect 
(MDI) 
42 37 6 
 Confidence about inhalation technique because of 
doctor’s satisfaction with technique 
 Could not distinguish device from medication  
P18 
Incorrect 
(MDI) 
36 25 
5 
 
 Overall dissatisfaction of having asthma effects the 
opinion of inhalers 
 Effectiveness of medication and long term usage lead to 
confidence about technique 
        P19 
 
Incorrect 
(MDI) 
49 42 7 
 Long term usage leads to confidence about technique 
 Could not distinguish medication from device 
 Long term usage leads to satisfaction with inhaler 
 Satisfaction with inhalers because of satisfaction with 
performance 
Incorrect 
(Turbuhaler®) 
37 40 6 
P20 
Incorrect 
(MDI) 
 
 
49 
39 7 
 
 Effectiveness of medication and long term usage lead to 
confidence about technique 
 Could not distinguish device from medication  
 Overall satisfaction with inhalers 
 
P21a 
 
 
 
Incorrect 
(MDI) 
 
 
45 39 7 
 
 Overall dissatisfaction with asthma and medication lead 
to dissatisfaction with inhalers 
 Confidence about technique because of effectiveness of 
medication 
 Could not distinguish device from medication 
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Participant Inhalation 
technique 
PASAPQ score Qualitative feedback 
Operation Convenience Overall 
satisfaction 
P22 
Incorrect 
(MDI) 
46 31 7 
  
 Long term usage leads to satisfaction with inhaler 
 Satisfaction with inhaler because of ease of use Incorrect 
(Turbuhaler®) 
 
46 36 7 
P23 
Incorrect 
(MDI) 
41 40 7 
 Could not distinguish device from medication 
 Confidence about technique because of effectiveness of 
medication 
 Satisfaction/dissatisfaction with medication influences 
opinion of device 
Incorrect 
(Turbuhaler®) 
36 37 4 
Incorrect 
(Accuhaler®) 
45 37 6 
P24 
Incorrect 
(MDI and 
MDI+ Spacer) 
 
46 37 6 
 
 Confidence about technique because of effectiveness of 
medication 
P25 
Incorrect 
(Turbuhaler®) 
43 39 6 
 Effectiveness of medication leads to confidence about 
technique 
 Effectiveness of medication leads to satisfaction with 
inhaler 
*Participant had 2 different inhaler and demonstrated correct technique for one of them and incorrect technique for other one.
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Discussion 
 
In this study we aimed to investigate the relationship between inhaler technique, 
patient satisfaction, preference and role of decision making with regards to 
inhalers. We found that, similar to other studies, a high proportion of participants 
did not use their inhalers correctly (24-28). We identified no relation between 
inhaler technique and patient perception and satisfaction with asthma inhalers or 
participant’s views on being actively involved in decision making i.e. having a choice 
in device selection. Rather, we found that device use, selection and preference 
were not considered in isolation by participants and were intrinsically linked to 
medication effectiveness, overall views about asthma management and belief that 
their health care providers could make decisions about medications for them. That 
is, other factors, unrelated to the device were influencing patient opinions of their 
inhalers.  
 
In an attempt to identify a relationship between inhaler technique, satisfaction 
with inhaler and attitudes and perceptions, a mixed method approach was taken. 
Although a number of studies have explored patient satisfaction with inhaler 
devices, a majority has taken a quantitative approach (53, 67-70). These have failed 
to add understanding to the relationship between patient’s satisfaction with 
devices, the notion of having a choice in selection of devices and how this might 
relate to their ability to use the inhalers correctly. If we are to address the issue of 
inhaler misuse (i.e. technique), then it is important to understand whether patient 
selection may make a difference. Triangulation of qualitative and quantitative data 
was able to explore this potential relationship.  
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Despite the common academic belief that inhalers as delivery devices are 
important in clinical effectiveness of medication, participants did not associate 
treatment efficacy with inhaler devices. From the participants’ perspective, the 
physical characteristics or features of an inhaler were not considered. Inhaler 
devices were not distinguished from the specific medications that they delivered 
and any opinions on then were collectively considered with regards to the 
participants’ perceptions of the effectiveness of their treatment in relieving and 
controlling asthma symptoms. That is, participants’ approaches towards their 
inhalers were intrinsically linked to their perceptions of asthma control and the side 
effects they experienced when using their medications. In that way, it can be said 
that asthma control and side effects, rather than inhaler characteristics were linked 
to satisfaction with inhalers. In fact, when participants were specifically asked to 
reflect on the features that they considered important in an inhaler, a number of 
them admitted they have never thought about it. This suggested that overall, 
inhaler devices themselves were insignificant when considering the use of 
medications in asthma management. 
 
In this study participants were burdened by the chronic nature of their asthma and 
the necessity of using inhalers in such a “dependent” and long-term way. An 
overwhelming majority of participant believed that having asthma meant that they 
were at risk of developing a dependency on their medications/inhalers. Participants 
expressed dissatisfaction with inhalers because of dissatisfaction with having 
asthma more generally. From the responses of participants in this study, it seems 
that for patients, inhaler devices as physical delivery systems play a minor role in 
their overall satisfaction with treatment. While on probing some mentioned the 
physical feature of the inhalers, overall satisfaction with inhaler devices was 
related, once again to the perceived effectiveness of asthma therapy and relief of 
asthma symptoms. One of the main inhaler-related factors which influenced their 
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satisfaction and confidence about inhalation technique was in fact, the length of 
time that they had been using the inhaler. This emergent information is perhaps 
controversial. It is highlighted in the literature that using inhaler for a long time 
enhances the chance of incorrect technique because with no technique 
reinforcement patients’ competency declines (24, 78, 79). Therefore, reassessment 
and reinforcement of inhalation technique is essential after the initial training and 
during therapy since studies shown patient will begin to demonstrate incorrect 
technique during time (80). It is significant to reinforce patients’ technique to 
ensure of retaining the correct technique (43). Participants did not report on ever 
receiving inhaler device education as a follow-up.  
 
When it come to confidence with inhaler devices, in addition to length of time of 
inhaler use, effectiveness of medication was viewed as a measure of correct use, as 
was the recount of having received instructions on use by the doctor. If a 
participant perceived that their inhaler was effective, they were confident in their 
ability to use it. Confidence based on the aforementioned criteria was somewhat 
misguided as despite the overwhelming confidence that participants felt they had 
with regards to their ability to use their inhalers, 88% of then did not. The 
mismatch of confidence with use and actual use of inhalers is not novel. This 
research is consistent with previous findings, which have shown that patients, who 
reported that their inhalers were easy to use, made major errors in inhalation 
technique (81). This mismatch highlights the focus on medication effectiveness and 
a lack of understanding of the fundamental aspects of medication use contributing 
to clinical outcomes. Participants did not consider that even if effective, with 
improved technique they may be able to decrease the dose of medication and 
reduce potential sides.  
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In this study we could not find any relationship between inhalation technique and 
satisfaction with inhalers; however the group with correct technique did differ to 
those who were not using their inhalers correctly. Those with correct inhaler 
technique clearly displayed a greater awareness of their asthma control and were 
clearly motivated to optimise it. The concept of motivation has previously been 
linked to inhaler technique in a recent study which indicated that patients who are 
motivated are more likely to demonstrate maintenance of correct technique over 
time (43).  
 
This study explored the level of choice and involvement of the participants in 
device selection. As expected, a majority of participants had not experienced any 
level of involvement in treatment decision-making, although it is highly recognized 
in literature that patient involvement in decision-making is important (50-52, 82). 
Lack of knowledge, insufficient physician time, reliance on a trusted physician to 
make decision and educated decision were the main reasons of non-involvement in 
this study. Despite the proposed association between having a choice and 
satisfaction with inhalers, a majority of the participants expressed satisfaction with 
their current passive role in asthma management and their inhalers and were 
content to rely on physicians’ decision to control their asthma. It can be hypothesis 
that in our study, the lack of desire for greater decision-making power is related to 
the level of knowledge of the participants. Reviewing the published literature, 
generally there are a limited number of studies which have specifically explored the 
level of asthma patient involvement in treatment decision-making and their 
expectation. Carees et al, (2002) employed a qualitative approach to explore the 
level of involvement in asthma treatment processes and patient perception (57). A 
collaborative role was the most preferred role amongst participants, which was 
followed by passive role. Research has shown that the main barriers to shared 
decision-making are trust in health professionals, patient level of knowledge (55), 
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lifelong nature of asthma and severity of the condition (57). Similar to our findings, 
in another study by Carees et al, (2005) the importance of patient and health care 
professionals’ education for collaboration in treatment process is emphasized 
when the passive role was the preferred role by 40% of participants, followed by 
36% preferring a collaborative approach and only 24% an active role (83).   
 
In exploring patient perception about their inhalers, as expected, the results 
relating to patient satisfaction were consistent between the data collected through 
interviews and the Patient Satisfaction and Preference Questionnaire (PASAPQ).  A 
majority of participants reported satisfaction with their inhalers. Consistent with 
the literature, ease of use was the most important feature of an inhaler regardless 
of the type of the device. Participants associated easy to use with their inhaler as 
being associated with better handling of the device, effectiveness in controlling 
symptoms and satisfaction and fulfillment with therapy. These factors were not 
related to actual ability to use their inhalers, hence it can be argued that while ease 
of use was important from the participants perspective, they did not have the 
knowledge to objectively evaluate if their perceived ease related to correct use. 
This is further exemplified in participants’ responses to particular devices. 
Participants reported pMDIs as being easy to use, even though it is well established 
that coordination of actuation and inhalation is one the most challenging steps, 
being done incorrectly by majority of patients (35, 36). In terms of DPIs, despite the 
satisfaction with ease of use, a number of participants were confused about 
performance of their device in general and loading the dose in particular. In fact, 
participants were unsure about correct administration of DPIs because they could 
not feel anything coming out of inhaler. In our study some of participants found 
DPIs complicated and confusing to use and expressed preference for their old 
fashion pMDIs because they could not feel it after inhalation. This is consistent with 
other published research, which has shown that patients perceive DPI more 
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difficult to use (78, 84). In addition, other physical features of inhalers including 
metered dose counter, portability and hygiene of use were important from the 
participant’s point of view. Participants were particularly aware of the dose counter 
expressing concern about running out of medication in emergency situations as a 
result of there being no dose counter on the device. From their perspective, the 
ideal inhaler would have a dose counter to ensure patients were aware of the 
remaining doses available. In several studies comparing various inhalers in a range 
of domains of convenience and performance, ease of use, hygiene, metered dose 
counter, portability and clear leaflet instruction were reported to be the most 
important inhaler features (85-87).  
 
In summary, this study suggests that, in contrast to current evidence relating to 
patient preference, there is no relationship between patient perception, 
satisfaction or decision-making power relating to inhaler devices and patient’s 
ability to use their devices correctly. The fact that participants could not 
differentiate the device from medication most certainly influenced their ultimate 
perception about inhalers. There are several other factors affecting not only 
patient opinion about asthma inhalers but also their perception about their 
inhalation technique and they are not necessarily related to the device. We found 
participants’ inhalation technique scores and their perceptions relating to their 
inhalation technique do not match in a majority of cases and certainly, satisfaction 
is not related to better inhaler technique. In fact, it appears that those participants 
who are more aware, knowledgeable or motivated to achieve good asthma control, 
are more likely to have correct inhaler technique. In addition, participant’s 
involvement in treatment decision-making is currently not on patient’s radar for 
asthma management or medication selection. It does not appear to be feasible in 
reality, potentially due to the patient’s lack of understanding of the role of inhalers, 
physician lack of time and the high level of trust that participant had for their 
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healthcare professionals, thereby removing the need for decision-making power. 
There is no indication that giving patients a choice in device selection alone will 
make any difference to the way they perceive their inhalers or their ability to use 
them correctly. However, investing time in explaining the technical importance of 
device use and the impact on the deposition of medication in the airways may 
improve understanding and help articulate the role of inhalers in asthma 
management and the importance of correct technique. The development of inhaler 
technique interventions, which include explanations of the technical importance of 
inhaler use, not only the consequences of misuse, should be developed and tested 
in the future.  
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Participant Information Statement 
 
Full Project Title: 
Inhaler Devices: Patient Preference and Technique 
This Participant Information Statement is 4 pages long. Please make sure you have 
all the pages. 
1. Your Consent 
You are invited to take part in a research project entitled “Inhaler Devices: Patient 
Preference and Technique” in which we seek to identify patient views about their 
inhalers. 
This Participant Information contains detailed information about the research 
project to help you decide whether or not you would like to take part in it. Please 
feel free to ask us any questions you might have. 
If you would like to participate in this project, you will be asked to sign the 
Consent Form, indicating that you understand the information and that you give 
your consent to participate in the research project. 
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You will be given a copy of the Participant Information and Consent Form to keep 
as a record. 
2. Purpose and Background 
For most people with asthma and other respiratory conditions, inhaler devices are 
used on a regular basis. Although there is a range of inhaler devices available, 
consumers often find them a challenge to use. The purpose of this project is to 
explore the attitudes, perception and preference of people with asthma regarding 
inhaler devices. By understanding the view of consumers we will be able to 
identify the things that are important to them and how this relates to the use of 
these inhalers.  
This study is being conducted by Ms Lia Jahedi ,a Mphil student at the Faculty of 
Pharmacy at the University of Sydney  to obtain her Master’s degree under 
supervision of Dr.Sinthia Bosnic-Anticevich and Dr.Bandana Siani and Professor 
Hak-Kim Chan from the Faculty of Pharmacy at the University of Sydney . 
3. Procedures and time duration 
Participation in this project will involve: 
 Filling out a ‘Patient Satisfaction and Preference Questionnaire’ (PASAPQ) 
which contains 16 questions. These questionnaires take about 10 minutes 
to finish. You are allowed to take the questionnaire home and finish them 
later if you need more time. We will give you a stamped self-addressed 
envelope so that you can mail them back to us.  
 Showing us how you would usually use your inhaler. 
 Telling us about your inhalers in a 15-20 minute face-to-face or telephone 
interview with the researcher (Ms.Lia Jahedi).The interview will be 
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conducted at the pharmacy or asthma clinic and will be tape recorded with 
your permission. 
4. Possible Benefits and Risks 
There are no risks associated with participating in this study and if you choose not 
to participate, there will be no long-term of short-term consequences associated 
with the care you receive. The primary  
benefit would be your contribution to the field of research into inhaler devices. 
This research may help to inform manufacturers of inhaler devices in the 
development of more user-friendly devices. You will also receive feedback on ways 
in which you can optimise the use of your inhaler through any modifications of 
your inhaler technique.  
5. Reimbursement for your costs 
You will receive a $30 gift card for the time associated with participation in this 
project.  
6. Privacy, Confidentiality and Disclosure of Information 
All aspects of the study including the results will be strictly confidential. All records 
will be de-identified and research data will not be able to be linked to any 
individual. Data will be stored in a locked secure area and only those persons 
identified above will have access to these records.  No information revealing any 
personal information such as your name, address or telephone number will leave 
the Faculty of Pharmacy at the Sydney University.  
Information gathered in this research study may be published or presented in 
public forums, however your name and other identifying information will not be 
used or revealed.  Despite efforts to keep your personal information confidential, 
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absolute confidentiality cannot be guaranteed. Your personal information may be 
disclosed if required by law. 
7. Participation is Voluntary 
Participation in any research project is voluntary. If you do not wish to take part 
you are not obliged to. If you decide to take part and later change your mind, you 
are free to withdraw from the project at any stage. You may stop interview at any 
time or change your mind while filling out the questionnaire, if you do not wish to 
continue, the audio recording will be erased and the information provided will not 
be included in the study.   
 
8. Further Information or Any Problems 
If you require further information or if you have any problems concerning this 
project you can contact the researcher (Ms Lia Jahedi) to answer your question 
and for more discussion .If you would like to know more at any stage, please feel 
free to contact 
  
Dr.Sinthia Bosnic-Anticevich, B.Pharm (Hons), PhD 
 Senior Lecturer 
 Faculty of Pharmacy, University of Sydney  
Telephone: 02 9351 5818 
Fax : 02 9351 4391 
Email: sinthia.bosnic-anticevich@sydney.edu.au 
 
9. Other Issues 
 
 
 
 
Any person with concerns or complaints about the conduct of a research study can 
contact The  Manager, Human Ethics Administration, University of Sydney on +61 2 
8627 8176 (Telephone); +61 2 8627 8177 (Facsimile) or ro.humanethics@sydney.edu.au 
(Email). 
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Participant Consent Form  
 
I .............................................. give consent to my participation in the research 
project entitled ‘patient preference and asthma inhalers’. 
By signing this consent I acknowledge that: 
  I have read the information and consent forms and have had my questions 
answered by them in a language I understand. The risks and benefits have 
been explained to me.  
 I believe that I have not been unduly influenced by any study team 
member to participate in the research study by any statements or implied 
statements. Any relationship (such as employer, supervisor or family 
member) I may have with the study team has not affected my decision to 
participate. 
 I understand that I will be given a copy of this consent form after signing it. 
 I understand that my participation in this study is voluntary and that I may 
choose to withdraw at any time. I freely agree to participate in this 
research study.   
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 I understand that information regarding my personal identity will be kept 
confidential and no information about me will be used in any way that 
reveals my identity. 
 
 I understand that I can stop the interview at any time if I do not wish to 
continue. The audio recording will be erased and the information provided 
will not be included in the study. I consent to 
 
 
 
i) Audio taping                                           YES                    NO   
ii) Receiving written transcripts               YES                    NO 
 
If you answered YES to the” Receiving the transcript for my interview 
questions (ii)”, please provide your details i.e. mailing address, email 
address. 
Address........................................................................................................................
.....................................................................................................................................
..................................................................................................................................... 
Email............................................................................................................................ 
 
  
By signing this consent form, I have not waived any of the legal rights that I have 
as a participant in a research study. 
  
Participant’s name …………………………………………………… 
Signature...........................................................               Date.............................        
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Declaration by researcher: I have given a verbal explanation of the research 
project, its procedures and risks and I believe that the participant has understood 
that explanation. 
 
Researcher’s name ………………………………………………     Date…………………………………. 
Signature..................................................................   Date.................................. 
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Inhaler Devices: Patient Preference and Technique 
 
 
 
 
 
 
 
 
 
 
 
     
    Ask your pharmacist about our research. 
   We are interested in getting feedback from consumers  
   about their inhalers and how they could be improved  
  also you will receive a gift voucher for your time. 
  For further information please contact: 
   Lia Jahedi, Mphil candidate 
Faculty of Pharmacy  
UNIVERSITY OF SYDNEY  
   Phone: 0414 1515 02 
   Email: ljah2603@uni.sydney.edu.au 
 
 
 
 
   Do you have Asthma? 
Do you us  an inhaler for your asthma or 
lung condition? 
   Would you like to help make them better? 
